The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target?

Current Drug Targets

Volumn 15, Issue 14, 2014, Pages 1284-1292

  Passiglia, Francesco ^a,h   Van Der Steen, Nele ^b   Raez, Luis ^c   Pauwels, Patrick ^a   Gil Bazo, Ignacio ^d   Santos, Edgardo ^e   Santini, Daniele ^f   Tesoriere, Giovanni ^g   Russo, Antonio ^h   Bronte, Giuseppe ^h   Zwaenepoel, Karen ^a   Cappuzzo, Federico ⁱ   Rolfo, Christian ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e Lynn Cancer Institute   (United States)

^f UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^g TEMPLE UNIVERSITY   (United States)

^h UNIVERSITY OF PALERMO   (Italy)

ⁱ ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

cMET; cMET Inhibitors; EGFR TKIs resistance; HGF; NSCLC; Targeted therapies

Indexed keywords

CABOZANTINIB; CRIZOTINIB; ERLOTINIB; FICLATUZUMAB; FOCAL ADHESION KINASE; FORETINIB; GEFITINIB; GLYCOGEN SYNTHASE KINASE 3BETA; GOLVATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; ONARTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; STAT PROTEIN; TAK 701; TIVANTINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL ADHESION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CLINICAL TRIAL (TOPIC); GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84920572810     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011514141216092739     Document Type: Article

References (78)

1. Torti D, Trusolino L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 2011; 3: 623-36.
2. Bronte G, Rizzo S, La Paglia L, et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 2010; 36 Suppl 3: S21-9.
3. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-smallcell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2493-501.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
5. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line singleagent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012; 30: 1122-8.
6. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.
7. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-8.
8. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42.
9. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-46.
10. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-34.
11. Yi Long Wuet-al LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as firstline treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol 31, 2013 (suppl; abstr 8016)
12. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
13. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010; 28: 357-60.
14. al. Ke. LCMC: Frequency of oncogenic drivers. In. J Thorac Oncol 2013; 8(Suppl 2): PL03.07.
15. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-43.
16. Wang W, Li Q, Takeuchi S, et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factorinduced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res 2012; 18: 1663-71.
17. Yamada T, Takeuchi S, Kita K, et al. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thorac Oncol 2012; 7: 272-80.
18. Yano S, Yamada T, Takeuchi S, et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011; 6: 2011-7.
19. Dean M, Park M, Le Beau MM, et al. The human met oncogene is related to the tyrosine kinase oncogenes. Nature 1985; 318: 385-8.
20. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984; 311: 29-33.
21. Jung W, Castren E, Odenthal M, et al. Expression and functional interaction of hepatocyte growth factor-scatter factor and its receptor c-met in mammalian brain. J Cell Biol 1994; 126: 485-94.
22. Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991; 6: 1997-2003.
23. Roletto F, Galvani AP, Cristiani C, et al. Basic fibroblast growth factor stimulates hepatocyte growth factor/scatter factor secretion by human mesenchymal cells. J Cell Physiol 1996; 166: 105-11.
24. Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995; 373: 699-702.
25. Bladt F, Riethmacher D, Isenmann S, et al. Essential role for the cmet receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995; 376: 768-71.
26. Rosário M, Birchmeier W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol 2003; 13: 328-35.
27. Chmielowiec J, Borowiak M, Morkel M, et al. c-Met is essential for wound healing in the skin. J Cell Biol 2007; 177: 151-62.
28. Rahmoune H, Rudland PS, Gallagher JT, Fernig DG. Hepatocyte growth factor/scatter factor has distinct classes of binding site in heparan sulfate from mammary cells. Biochemistry 1998; 37: 6003-8.
29. Donate LE, Gherardi E, Srinivasan N, et al. Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Protein Sci 1994; 3: 2378-94.
30. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22: 309-25.
31. Fixman ED, Fournier TM, Kamikura DM, et al. Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein. J Biol Chem 1996; 271: 13116-22.
32. Weidner KM, Di Cesare S, Sachs M, et al. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996; 384: 173-6.
33. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834-48.
34. Rodrigues GA, Park M, Schlessinger J. Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J 1997; 16: 2634-45.
35. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994; 77: 261-71.
36. Mesteri I, Schoppmann SF, Preusser M, Birner P. Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma. Eur J Cancer 2014; 50: 1354-60.
37. Fan S, Gao M, Meng Q, et al. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 2005; 24: 1749-66.
38. Chen SY, Chen HC. Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion. Mol Cell Biol 2006; 26: 5155-67.
39. Carter S, Urbé S, Clague MJ. The met receptor degradation pathway: requirement for Lys48-linked polyubiquitin independent of proteasome activity. J Biol Chem 2004; 279: 52835-9.
40. Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected nonsmall- cell lung cancer patients. J Clin Oncol 2009; 27: 1667-74.
41. Di Renzo MF, Olivero M, Martone T, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000; 19: 1547-55.
42. Ma PC, Tretiakova MS, MacKinnon AC, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008; 47: 1025-37.
43. Rodrigues GA, Naujokas MA, Park M. Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing. Mol Cell Biol 1991; 11: 2962-70.
44. Corso S, Giordano S. Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective. Cancer Discov 2013; 3: 978-92.
45. Wang W, Li Q, Yamada T, et al. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2009; 15: 6630-8.
46. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3: 347-61.
47. Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17: 77-88.
48. MarkM Z-W, SuYet al. Combination efficacy with MetMAb and erlotinib in a NSCLC tumor model highlight therapeutic opportunities for c-Met inhibitors in combination with EGFR inhibitors. In. Presented at the 99th American Association for Cancer Research Annual Meeting, San Diego, CA, April 12–16, 2008.
49. Stabile LP, Rothstein ME, Keohavong P, et al. Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice. Cancers (Basel) 2010; 2: 2153-70.
50. Zhang YW, Staal B, Essenburg C, et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 2010; 70: 6880-90.
51. Tang Z, Du R, Jiang S, et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 2008; 99: 911-22.
52. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12: 6144-52.
53. Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013; 31: 4105- 14.
54. Koeppen H, Yu W, Zha J, et al. Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib {+/-} Onartuzumab in Advanced Non-Small-Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit. Clin Cancer Res 2014.
55. Spigel DR. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. In J Clin Oncol 32: 5s, 2014 (suppl; abstr 8000).
56. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006; 103: 2316-21.
57. al. EAe. Met heterogeneity evaluation by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in nonsquamous non-small cell lung cancer (nsNSCLC). In J Clin Oncol 32:5s, 2014 (suppl; abstr 11005).
58. Tan E PK, Lim WT, et al. Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. In J Clin Oncol 2011; 29(Suppl 15): Abstract 7571
59. Mok TS PK, Geater SL, et al. A randomized phase 2 study with exploratory biomarker analysis of ficlatuzumab a humanized hepatocyte growth factor inhibitory MAB in combination with gefitinib versus gefitinib in Asian patients with lung adenocarcinoma. In. Ann Oncol 2012; 23: abstr 1198P.
60. Gordon MS, Sweeney CS, Mendelson DS, et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010; 16: 699-710.
61. Jones SF CR, Bendell JC, et al. Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced non hematologic malignancies: First-in-human phase I dose-escalation study. In. J Clin Oncol 2010; 28: abstr 3081.
62. Hori A, Kitahara O, Ito Y, Nishizawa S, et al. Monotherapeutic and combination antitumor activities of TAK-701, a humanized antihepatocyte growth factor neutralizing antibody, against multiple types of cancer. In. American Association for Cancer Research (AACR) Annual Meeting; Denver, CO. 2009.
63. Eathiraj S, Palma R, Volckova E, et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c- Met) protein autophosphorylation by ARQ 197. J Biol Chem 2011; 286: 20666-76.
64. Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011; 29: 3307-15.
65. Rodig S SL, von Pawel J, et al. An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2 study. In. Presented at: Annual Meeting of the American Association for Cancer Research; March 31-April 4, 2012; Chicago (IL). Abstract 1729
66. Scagliotti GV, Novello S, Schiller JH, et al. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer 2012; 13: 391-5.
67. al. Se. MARQUEE: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Non-squamous, Non-small-cell Lung Cancer (NSCLC). In. Presented at the 17th ECCO – 38th ESMO – 32nd ESTRO European Cancer Congress, 2013. (Abstract 3410).
68. al. Re. In. J Clin Oncol 2014; 32 (suppl 5; abstr 8014).
69. Hellerstedt BA EG, Vogelzang NJ, et al. Activity of cabozantinib (XL184) in metastatic NSCLC: results from a phase II randomized discontinuation trial (RDT). In. J Clin Oncol 2012; 30 Suppl: Abstr 7514.
70. Peters S, Adjei AA, Gridelli C, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 Suppl 7: vii56-64.
71. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007; 6: 3314-22.
72. Kwak E, Camidge D, Clark J. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF- 02341066. In. ASCO Annual Meeting: 7(suppl): abstract 3509 2009.
73. Tanizaki J, Okamoto I, Okamoto K, et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MEt alterations. J Thorac Oncol 2011; 6: 1624-31.
74. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011; 6: 942-6.
75. Schwab R, Petak I, Kollar M, et al. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer 2014; 83: 109-11.
76. Camidge DR OS, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). In. abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract 8001.
77. Liu L, Shi H, Liu Y, et al. Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. Mol Cancer Ther 2011; 10: 518-30.
78. Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-smallcell lung cancer patients. Ann Oncol 2009; 20: 298-304.